Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.

Original reporting
Published Nov 6, 2026, 3:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 3:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astrana Health Q3 Earnings Call Highlights — source image
Decision brief

The 30-second read

$ASTHNeutralMed
01

Why it matters

The guidance mix of growth in Medicare Advantage and Medicaid challenges may lead to a modest re‑rating of the stock's valuation.

02

Market read

First‑hand earnings call data provides fresh insight for traders evaluating ASTH's near‑term valuation and sector positioning.

03

What to watch

Potential impact of the pending cyber‑incident investigation on operational risk and future cost structure.

Relevance 7/10Novelty 7/10Timing: after‑hours following Q3 earnings release

Background

Astrana Health (NASDAQ:ASTH) reported Q3 results, membership trends, and forward‑looking guidance for 2027, including a recent acquisition and new Medicare partnerships.

Company-level read

Ticker impact

$ASTHNeutralHigh confidence
Context

Q3 earnings call disclosed membership growth, Medicaid attrition assumptions, full‑risk capitation targets and a tuck‑in acquisition, providing fresh guidance for 2027.

Expected impact

likely slight downside pressure as investors weigh Medicaid attrition against Medicare growth

Evidence & confidence

The new guidance introduces a mid‑single‑digit EBITDA headwind and outlines capitation revenue targets, which may temper enthusiasm despite Medicare upside.

Market effects

Signals continued shift toward full‑risk Medicare contracts in the value‑based care sector.

Texas market may see increased investor interest due to strong performance of global‑risk arrangements.

Highlights broader industry trend of Medicare Advantage capitation growth.

Counterpoint

Investors could view the Medicaid attrition and cost headwinds as a catalyst for a sharper price correction.

Key entities

  • Astrana Health

    Healthcare enablement firm providing value‑based care solutions.

  • Sim

    CEO who presented the earnings call.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.